<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05045417</url>
  </required_header>
  <id_info>
    <org_study_id>Soh-Med-21-09-22</org_study_id>
    <nct_id>NCT05045417</nct_id>
  </id_info>
  <brief_title>IL17 in Systemic Lupus Erythematosus Patients: Association With Disease Activity and Organ Damage</brief_title>
  <official_title>IL17 in Systemic Lupus Erythematosus Patients: Association With Disease Activity and Organ Damage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many laboratory markers can be measured for assessment of Lupus activity as aberrant&#xD;
      manufacturing and imbalance of the cytokines of T-helper cell which already have been&#xD;
      implicated within autoimmunity pathogenesis as IL-18 and IL-10 levels are usually elevated in&#xD;
      lupus sufferers and correlated with SLEDAI score IL-17 has been linked to immune-mediated&#xD;
      organ damage in several autoimmune diseases and recently it has been linked to pathogenesis&#xD;
      of a murine model of lupus and human lupus Diverse cytokine abnormalities which common in&#xD;
      lupus patients may skew T cells differentiation into IL-17-producing CD4+ and double negative&#xD;
      T cells. This could promote the autoimmune process by activation of immune cells &amp;stimulation&#xD;
      of proliferation of B-cell and production of antibody&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>SLE disease activity index (SLEDAI)</measure>
    <time_frame>18 Months</time_frame>
    <description>• Assessment of the disease activity in the patients will be done by using the SLE disease activity index (SLEDAI). It potentially measures reversible manifestations of the underlying inflammatory disease process. The scale includes24 &quot;weighted&quot; attribute grouped into 9 domains. The final score is the sum of all attributed scores.&#xD;
No activity 0&#xD;
mild activity: 1-5&#xD;
moderate activity: 6- 1 0&#xD;
high activity : 1 1 - 1 9&#xD;
very high &gt; 20</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Cases with SLE</arm_group_label>
    <description>110 patients with SLE will be divided to :&#xD;
40 patients with lupus nephritis&#xD;
40 patients interstitial lung disease&#xD;
30 SLE patients without internal organ affection)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>30 sex and age matched healthy individuals as a control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Serum level of IL-17</intervention_name>
    <description>Measurement of serum level of IL-17 :&#xD;
To explore the role of IL-17 in systemic lupus erythematosus&#xD;
To determine the relation between IL-17 and lupus disease activity&#xD;
To analyze the correlation between IL-17 and internal organ affection (lupus nephritis , interstitial lung disease)</description>
    <arm_group_label>Cases with SLE</arm_group_label>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  The study will include 110 patients with SLE :&#xD;
&#xD;
               -  40 with lupus nephritis&#xD;
&#xD;
               -  40 with interstitial lung disease&#xD;
&#xD;
               -  30 SLE patients without internal organ affection)&#xD;
&#xD;
          -  In addition to 30 sex and age matched healthy individuals as a control group&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  SLE will be diagnosed according to the 2012 Systemic Lupus International Collaborating&#xD;
             Clinics (SLICC) classification criteria for SLE&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Patients who are able and willing to give written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -Any other autoimmune disease rather than SLE. -&#xD;
&#xD;
          -  Systemic diseases&#xD;
&#xD;
          -  Malignancy&#xD;
&#xD;
          -  pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aya M Ahmed, assistant lecturer</last_name>
    <phone>01013325505</phone>
    <email>aya.ali1@med.sohag.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Faten E Mohamed, professor</last_name>
    <phone>01066881548</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sohag University Hospital</name>
      <address>
        <city>Sohag</city>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Osama R ElSherif, professor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Crispín JC, Tsokos GC. IL-17 in systemic lupus erythematosus. J Biomed Biotechnol. 2010;2010:943254. doi: 10.1155/2010/943254. Epub 2010 Apr 6. Review.</citation>
    <PMID>20379379</PMID>
  </reference>
  <reference>
    <citation>Garrett-Sinha LA, John S, Gaffen SL. IL-17 and the Th17 lineage in systemic lupus erythematosus. Curr Opin Rheumatol. 2008 Sep;20(5):519-25. doi: 10.1097/BOR.0b013e328304b6b5. Review.</citation>
    <PMID>18698171</PMID>
  </reference>
  <reference>
    <citation>Su DL, Lu ZM, Shen MN, Li X, Sun LY. Roles of pro- and anti-inflammatory cytokines in the pathogenesis of SLE. J Biomed Biotechnol. 2012;2012:347141. doi: 10.1155/2012/347141. Epub 2012 Feb 15. Review.</citation>
    <PMID>22500087</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 12, 2021</study_first_submitted>
  <study_first_submitted_qc>September 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>September 12, 2021</last_update_submitted>
  <last_update_submitted_qc>September 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Aya Mohamed Ali</investigator_full_name>
    <investigator_title>Assistant lecturer of rheumatology and rehabilitation sohag university hospitals</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

